Anthropic Launches AI for Science Rare Disease Research Grants

On July 16, 2026, Anthropic announced a special grant for rare genetic disease research under its "AI for Science" program. Since its launch in spring 2025, the program has supported drug repurposing, quantum simulation, and other projects. This special grant aims to build a researcher community through themed project calls, using AI to address fundamental challenges in rare disease research.

The rare disease field faces issues such as fragmented data, small patient populations, and isolated mechanism research. Approximately 400 million people worldwide are affected by over 7,000 rare diseases, but each disease has very few patients, making clinical registration, target identification, and trial design difficult. AI is seen as capable of modeling rare genetic diseases, detecting patterns across diseases, synthesizing literature findings, extracting information from limited data, and creating shared terminology.

Track 1 (Basic Science) aims to foster collaboration among clinical researchers, patient organizations, and data scientists to accelerate basic science progress and rare disease mechanism discovery. Early partner Monarch Initiative has developed the Mondo disease ontology and Monarch knowledge graph, and recently launched an agent-based mechanistic disease classification library, DisMech. Claude can read case reports, variant databases, registry patterns, etc., to point out mechanistic similarities between diseases at unprecedented speed and scale.

Track 2 (Biotechnology) supports early-stage biotech companies to accelerate rare disease drug development. Currently, it takes 1-2 years from diagnosis to treatment, with much time spent queuing for production, sequential safety trials, and manual regulatory document preparation. Anthropic believes Claude can compress these steps, particularly through automating document preparation (e.g., drafting and reviewing regulatory dossiers), accelerating treatment strategy selection (e.g., analyzing target druggability across different drug modalities), and finding shared mechanisms among individual gene therapies, potentially speeding approval via "basket trials" rather than individual IND applications for each patient.

Anthropic lists three existing AI for Science grantees as examples. Every Cure uses Claude to identify repurposing opportunities among millions of drug candidates; Centre for Population Genomics builds a Claude-based system to automatically draft variant classifications for expert review, addressing one of the biggest bottlenecks in rare genetic disease diagnosis; Violet Research Institute uses Claude to navigate FDA guidelines, run bioinformatics pipelines, analyze experimental data, and draft regulatory documents.

These cases show that Claude's application in rare diseases already covers multiple stages from basic mechanism discovery to preclinical development. Anthropic hopes new grantees can amplify and emulate these efforts.

The application deadline is August 2, 2026, at 23:59 Pacific Time. Grantees can use the credits to access Claude Opus or other general models approved for biological research. Projects that may touch biological classifiers can apply for an exemption. Anthropic provides example projects for Track 1: proposing and ranking mechanistic links between different rare diseases (verifiable in Monarch's DisMech); collating and summarizing patient organization data to improve natural history studies; building benchmarks to evaluate model capabilities in rare disease tasks.